SCHEMBL18172845

SCHEMBL18172845

Cc1ccccc1CN(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.40
HSP90AA1 P07900 1/20 0.39
MAOB P27338 1/20 0.39
HPGD P15428 3/20 0.38
ALDH1A1 P00352 3/20 0.38
CTBP2 P56545 1/20 0.38
KDM4E B2RXH2 2/20 0.38
TAS2R14 Q9NYV8 1/20 0.38
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
JAK2 O60674 1/20 0.38
S1PR4 O95977 1/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
PKM P14618 1/20 0.38
ALOX15 P16050 1/20 0.38
XBP1 P17861 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30264826 0.85 HSP90AA1 (0.47) TSHRHSP90AA1ALDH1A1KDM4EBCHE
SCHEMBL1626936 0.84 TSHR (0.40) TSHRHPGDALDH1A1KDM4ETDP1
SCHEMBL19716900 0.84 TSHR (0.41) TSHRHSP90AA1MAOBHPGDALDH1A1
SCHEMBL1845414 0.83 AKR1B1 (0.43) HPGDALDH1A1MEN1KMT2ATDP1
SCHEMBL18173003 0.82 AKT1 (0.43) AKT1
SCHEMBL798304 0.81 SMN1; SMN2 (0.44) TSHRHPGDALDH1A1CTBP2KDM4E
SCHEMBL6682105 0.81 PRKCI (0.37) TSHRALDH1A1ACHEKMT2AMAPK1
SCHEMBL13656744 0.81 NR1D1 (0.40) TSHRAKT1
SCHEMBL24891920 0.80 GRM2 (0.36) TSHRALDH1A1ACHEMAPK1HTT
SCHEMBL30182580 0.80 GRM2 (0.36) TSHRALDH1A1ACHEMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3286172-B1 LSD1 INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS INC (US) 2019-06-12 EP disclosed
EP-3286172-B1 LSD1 INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS INC (US) 2019-06-12 EP disclosed
US-20180290976-A1 LSD1 INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. 2018-10-11 US disclosed
EP-3286172-A1 LSD1 INHIBITORS AND USES THEREOF Constellation Pharmaceuticals, Inc. (US) 2018-02-28 EP disclosed
WO-2016202253-A1 NRF2 REGULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2016-12-22 WO disclosed
WO-2016172496-A1 LSD1 INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. (US) 2016-10-27 WO disclosed
WO-2016172496-A1 LSD1 INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. (US) 2016-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180290976-A1 LSD1 INHIBITORS AND USES THEREOF KDM1B, KDM1A, KDM2A TSHR 4232/4885HSP90AA1 3818/4885MAOB 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.